IMUX IMMUNIC, INC.

NEUTRAL Impact: 4/10 8-K
Horizon immediate Filed Apr 14, 2026 Processed 1mo ago SEC 0001193805-26-000461
8-K context-dependent: Items 8.01
Latest settled — T+20d
IMUX ▲ +7.21% at T+20d
NEUTRAL call ✓ call won +7.21% · α vs SPY +1.16% · entry $11.10 → $11.90
Next anchor: T+60d in 7w
Last close $13.05 (close May 22) · +17.57% from $11.10 entry
Entry anchored
Apr 14, 03:59 PM ET
via Databento tick
T+1d
-9.91%
call -9.91% · α -10.16%
$10.00
settled 6w ago
T+5d
-18.92%
call -18.92% · α -20.56%
$9.00
settled 5w ago
T+20d
+7.21%
call +7.21% · α +1.16%
$11.90
settled 12d ago
T+60d
call — · α —
in 7w

Price Chart

Loading chart...

Executive Summary

Immunic, Inc. (IMUX) announced that shareholders approved a proposal to authorize the board to implement a reverse stock split at a ratio between 1-for-10 and 1-for-30. Following the vote, the board approved a 1-for-10 reverse stock split effective April 27, 2026. The new shares will trade under the same ticker IMUX with a new CUSIP.

Actionable Insight

Traders should anticipate reduced liquidity and potentially increased volatility following the reverse stock split. The move is typically aimed at meeting exchange listing requirements or improving market perception, but does not alter the company's fundamentals. Monitor trading volume and bid-ask spreads after April 27.

Key Facts

  • Shareholders approved a proposal authorizing the board to execute a reverse stock split within a range of 1-for-10 to 1-for-30.
  • The board subsequently approved a 1-for-10 reverse stock split.
  • The reverse stock split is expected to be effective at 12:01 a.m. Eastern Time on April 27, 2026.
  • New shares will begin trading on the Nasdaq Capital Market on April 27, 2026 under the existing ticker symbol IMUX with a new CUSIP of 4525EP200.
  • 57,404,749 votes were cast in favor, 12,594,555 against, and 623,363 abstained.

Financial Impact

The reverse stock split will reduce the number of outstanding shares by approximately 90% (1-for-10 ratio), increasing the per-share price proportionally without changing the company's market capitalization of $159M.

share countshare priceliquiditymarket perception

Risk Factors

  • Potential for decreased trading liquidity due to fewer shares outstanding.
  • Market perception of reverse splits as a sign of financial distress, despite no fundamental change.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193805-26-000461
Document: 0001193805-26-000461-index-headers.html0001193805-26-000461
Document: 0001193805-26-000461-index.html0001193805-26-000461
Document: 0001193805-26-000461.txt0001193805-26-000461
7 reports for IMUX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for IMUX — sortable, filterable
Type Now
May 19, 2026
4d ago
3
NEUTRAL ★ 2/10
awaiting T+5
May 19, 2026
4d ago
8-K
NEUTRAL ★ 3/10
awaiting T+5
Apr 30, 2026
23d ago
S-3/A
BEARISH ★ 8/10
$9.65 $11.75▼ −21.76%▼ −19.41%$13.05 (−35.23%)
Apr 23, 2026
4w ago
8-K
NEUTRAL ★ 4/10
$9.18 $10.03▲ +9.26%▲ +7.78%$13.05 (+42.16%)
Apr 14, 2026
5w ago
8-K
NEUTRAL ★ 4/10
$11.10 $9.00▼ −18.92%▼ −20.56%$13.05 (+17.57%)
Apr 10, 2026
6w ago
8-K
NEUTRAL ★ 3/10
$12.20 $9.55▼ −21.72%▼ −25.02%$13.05 (+6.97%)
Feb 26, 2026
12w ago
8-K
BULLISH ★ 8/10
$9.48 $11.10▲ +17.09%▲ +18.22%$13.05 (+37.66%)
Showing 7 of 7

US Market Status

Market Closed — Opens Tue (34h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access